Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision making
Carrying out these actions will facilitate the development of methodological best practices for generating RWE to inform HTA of highly innovative medicines and build trust between stakeholders in the use of RWE.
Authors
- Piia Rannanheimo
- Matti Aapro (ORCID: https://orcid.org/0000-0003-3570-8319)
- Ashley Jaksa (ORCID: https://orcid.org/0000-0003-3571-3345)
- Laurie Lambert (ORCID: https://orcid.org/0000-0002-6840-7531)
- Victoria Hodgkinson (ORCID: https://orcid.org/0000-0001-5908-2694)
- Michael Hecht Olsen (ORCID: https://orcid.org/0000-0003-2230-5780)
- Karen Facey (ORCID: https://orcid.org/0000-0001-6670-5271)
- Niklas Hedberg
- François Meyer
- Alina N Pavel
Institutions
- Luminex (United States) (US)
- Canadian Agency for Drugs and Technologies in Health (CA)
- Allen Institute for Brain Science (US)
- University of Calgary (CA)
- Clinique de Genolier (CH)
- Aetion (United States) (US)
- Swedish Dental Association (SE)
- Flint Institute Of Arts (US)
- Finnish Medicines Agency Fimea (FI)
- Hotchkiss Brain Institute (CA)
- European X-Ray Free-Electron Laser (DE)
- University of Edinburgh (GB)
Publication Details
- Journal
- International Journal of Technology Assessment in Health Care
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s0266462325100238
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- Pfizer
- AstraZeneca
- Gilead Sciences